- Highline =>Spotting Opportunities in High Growth Markets.
- Posts
- Trapped in the Cycle: Unfulfilled Weight Loss Dreams
Trapped in the Cycle: Unfulfilled Weight Loss Dreams
GLP-1s Unveiled: Transforming the Landscape of Healthcare
Miles Galli
November 28, 2023
Feedback
Hi Guys, I'm looking for some feedback on these emails.
Do you find them helpful?
Do they encourage you to listen to the podcast?
Are they too short/long?
What do you want to see more/less of?
Please email me at [email protected]. I would really appreciate your help!
Podcast Link:https://open.spotify.com/show/2gwZ88PmWkzDW9dC9bosy1
YouTube: https://youtu.be/-QjBnXYm_RU
Top Ideas From The Podcast:
In this episode, we explore GLP-1s, drugs that offer new treatment possibilities for obesity and diabetes.
What are GLP-1s?
The Growth of the company that created it?
How big is the weight loss market?
Dialogue design.
My top idea for the podcast.
Obestity at No 3, dunno about you, but this shocked me.
Revolutionizing Health the GLP-1 Breakthrough
What are GLP-1s
GLP-1s are medications based on a hormone that regulates blood sugar. Novo Nordisk developed 'semaglutide', a molecule mimicking the natural GLP-1 hormone, useful in managing type-2 diabetes. After initial struggles, Novo Nordisk's introduction of Ozempic in 2017, approved for diabetes treatment and weight loss, marked a significant success.
Novo Nordisk’s Growth
Novo Nordisk's growth reflects the pharmaceutical industry's dynamic nature. Ozempic, contributing to significant patient weight loss in trials, has propelled the company's revenue, with projections reaching $1.8 billion in 2023. The company's market value doubled in the same year, reflecting the drug's commercial success.
Novo Nordisk, which had a market cap of USD 200B at the start of the year has increased to USD 400B right now in 2023. Novo Nordisk has a larger market cap than Denmark’s GDP!!
The Weight Loss Market
Obesity affects over 1 billion people globally, with 42% of Americans classified as obese. The demand for effective weight loss solutions is clear, and GLP-1s like Ozempic could meet this need. Novo Nordisk's market capitalization, exceeding Denmark's GDP, illustrates the market's potential.
Learnings:
Design for Dialougue
Create products that speak to human needs and will speak for themselves. Take eight sleep. Sleep is critical to our overall health and well-being. People can tell if you are not sleeping; it's a fundamental part of our health. If you have a great night’s sleep, you will tell someone about it.
Yes, the 8 Sleeps product is amazing, but it’s also correlated with something deeply important to human behaviour.
Similarly, weight loss products are intimately connected to self-image and health—two areas that are deeply significant to most people. Improvements in these areas are often immediately noticeable and, as such, become a talking point for individuals, creating natural opportunities for word-of-mouth marketing.
Our strategic advantage lies in understanding and leveraging these inherent behavioural patterns. By designing products that naturally fit into people's existing conversations about their daily lives—such as their health, sleep quality, and self-esteem—we can create offerings with built-in marketing potential.
Action: Create a list of behaviours that create inherent word of mouth.
Top Idea From the Podcast
Expanding on the podcast's key idea, the challenge GLP-1s is keeping the weight off after you stop taking them. Therefore, there is a real opportunity here to create comprehensive weight loss programs with psychological support, focusing on emotional and mental well-being during the weight loss journey. Specifically targeted to people of GLP-1 drugs.
